Intelomed, Inc. Receives CE Marking, Plans to Expand Business Beyond the United States
Intelomed, Inc. received CE Marking this week, thus allowing it to expand its marketing efforts beyond the United States. "Obviously, achieving CE Mark is critical to our global strategy, said Frank Amoruso, President and CEO. "CVInsight, our non-invasive tool for assessing and monitoring cardiovascular stress, can be of great value in many areas of health care, both in the United States and across the globe."Read more...
Intelomed, Inc. Named Pittsburgh Tech 50 Awards Finalist
Intelomed, Inc., developer of CVInsight®, a solution to noninvasively monitor physiologic stress placed on the cardiovascular system, announced today that the Pittsburgh Technology Council has named it a Tech 50 Awards Finalist in the Innovator of the Year Category.Read more...
Intelomed Receives FDA 510(k) Clearance of CVInsight™ Medical Device
Intelomed, Inc., a developer of non-invasive medical devices and technology for monitoring fluid adaptation for patients well or poorly perfused, announced today that it has received FDA 510(k) clearance on its CVInsight™ medical device.Read more...
Intelomed Raises $4M with Series A-1 Round
On September 9, 2013 Intelomed, Inc. announced it had secured $4 million in funding from new and existing shareholders through the sale of its Series A-1 Common Preferred stock.Read more...